<DOC>
	<DOC>NCT01790308</DOC>
	<brief_summary>The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.</brief_summary>
	<brief_title>Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function</brief_title>
	<detailed_description>The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.liraglutide combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>newly diagnosed type 2 diabetes fasting blood glucose (FBG) level ranging from 7.016.7mmol/L body mass index (BMI) ranging from 2135kg/m2 antihypercaemic and antihyperlipidemic medicationnaive patients having any severe acute or chronic diabetic complications renal dysfunction, blood creatinine&gt;150umol/L blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT) any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months chronic or acute pancreatic disease severe systemic diseases or malignant tumor female patients incline to be pregnant being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>